215 related articles for article (PubMed ID: 23379899)
1. βIII-Tubulin: biomarker of taxane resistance or drug target?
Karki R; Mariani M; Andreoli M; He S; Scambia G; Shahabi S; Ferlini C
Expert Opin Ther Targets; 2013 Apr; 17(4):461-72. PubMed ID: 23379899
[TBL] [Abstract][Full Text] [Related]
2. Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies.
Dumontet C; Jordan MA; Lee FF
Mol Cancer Ther; 2009 Jan; 8(1):17-25. PubMed ID: 19139109
[TBL] [Abstract][Full Text] [Related]
3. βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
Smiyun G; Azarenko O; Miller H; Rifkind A; LaPointe NE; Wilson L; Jordan MA
Cancer Chemother Pharmacol; 2017 Jul; 80(1):151-164. PubMed ID: 28567478
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of action of ixabepilone and its interactions with the βIII-tubulin isotype.
Lopus M; Smiyun G; Miller H; Oroudjev E; Wilson L; Jordan MA
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1013-24. PubMed ID: 26416565
[TBL] [Abstract][Full Text] [Related]
5. Tubulin: an example of targeted chemotherapy.
Seligmann J; Twelves C
Future Med Chem; 2013 Mar; 5(3):339-52. PubMed ID: 23464522
[TBL] [Abstract][Full Text] [Related]
6. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
Cai P; Lu P; Sharom FJ; Fang WS
Cancer Lett; 2013 Dec; 341(2):214-23. PubMed ID: 23941826
[TBL] [Abstract][Full Text] [Related]
7. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.
Kang CH; Jang BG; Kim DW; Chung DH; Kim YT; Jheon S; Sung SW; Kim JH
Lung Cancer; 2010 Jun; 68(3):478-83. PubMed ID: 19683826
[TBL] [Abstract][Full Text] [Related]
8. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy.
Dumontet C; Isaac S; Souquet PJ; Bejui-Thivolet F; Pacheco Y; Peloux N; Frankfurter A; Luduena R; Perol M
Bull Cancer; 2005 Feb; 92(2):E25-30. PubMed ID: 15749640
[TBL] [Abstract][Full Text] [Related]
9. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.
Sève P; Reiman T; Dumontet C
Lung Cancer; 2010 Feb; 67(2):136-43. PubMed ID: 19828208
[TBL] [Abstract][Full Text] [Related]
10. Modification of C-seco taxoids through ring tethering and substituent replacement leading to effective agents against tumor drug resistance mediated by βIII-Tubulin and P-glycoprotein (P-gp) overexpressions.
Tang Y; Rodríguez-Salarichs J; Zhao Y; Cai P; Estévez-Gallego J; Balaguer-Pérez F; Redondo Horcajo M; Lucena-Agell D; Barasoain I; Díaz JF; Fang WS
Eur J Med Chem; 2017 Sep; 137():488-503. PubMed ID: 28624703
[TBL] [Abstract][Full Text] [Related]
11. Ixabepilone: a new microtubule-targeting agent for breast cancer.
Higa GM; Abraham J
Expert Rev Anticancer Ther; 2008 May; 8(5):671-81. PubMed ID: 18471040
[TBL] [Abstract][Full Text] [Related]
12. Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.
Murray S; Briasoulis E; Linardou H; Bafaloukos D; Papadimitriou C
Cancer Treat Rev; 2012 Nov; 38(7):890-903. PubMed ID: 22465195
[TBL] [Abstract][Full Text] [Related]
13. Taxanes with high potency inducing tubulin assembly overcome tumoural cell resistances.
Matesanz R; Trigili C; Rodríguez-Salarichs J; Zanardi I; Pera B; Nogales A; Fang WS; Jímenez-Barbero J; Canales A; Barasoain I; Ojima I; Díaz JF
Bioorg Med Chem; 2014 Sep; 22(18):5078-90. PubMed ID: 25047938
[TBL] [Abstract][Full Text] [Related]
14. Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer.
De Donato M; Mariani M; Petrella L; Martinelli E; Zannoni GF; Vellone V; Ferrandina G; Shahabi S; Scambia G; Ferlini C
J Cell Physiol; 2012 Mar; 227(3):1034-41. PubMed ID: 21520077
[TBL] [Abstract][Full Text] [Related]
15. [Class III beta tubulin expression in nonsmall cell lung cancer].
Sève P; Dumontet C
Rev Mal Respir; 2010 Apr; 27(4):383-6. PubMed ID: 20403547
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of βIII-tubulin (TUBB3) expression in human normal tissues and cancers.
Person F; Wilczak W; Hube-Magg C; Burdelski C; Möller-Koop C; Simon R; Noriega M; Sauter G; Steurer S; Burdak-Rothkamm S; Jacobsen F
Tumour Biol; 2017 Oct; 39(10):1010428317712166. PubMed ID: 29022485
[TBL] [Abstract][Full Text] [Related]
17. Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.
Ploussard G; Terry S; Maillé P; Allory Y; Sirab N; Kheuang L; Soyeux P; Nicolaiew N; Coppolani E; Paule B; Salomon L; Culine S; Buttyan R; Vacherot F; de la Taille A
Cancer Res; 2010 Nov; 70(22):9253-64. PubMed ID: 21045157
[TBL] [Abstract][Full Text] [Related]
18. Effects of eribulin on microtubule binding and dynamic instability are strengthened in the absence of the βIII tubulin isotype.
Wilson L; Lopus M; Miller HP; Azarenko O; Riffle S; Smith JA; Jordan MA
Biochemistry; 2015 Oct; 54(42):6482-9. PubMed ID: 26435331
[TBL] [Abstract][Full Text] [Related]
19. Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin.
Gan PP; McCarroll JA; Po'uha ST; Kamath K; Jordan MA; Kavallaris M
Mol Cancer Ther; 2010 May; 9(5):1339-48. PubMed ID: 20442307
[TBL] [Abstract][Full Text] [Related]
20. CCR 20th anniversary commentary: BMS-247550—microtubule stabilization as successful targeted therapy.
Pabla N; Sparreboom A
Clin Cancer Res; 2015 Mar; 21(6):1237-9. PubMed ID: 25770292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
